CN103520139A - 一种肺吸入槲皮素纳米微球及其制备方法 - Google Patents
一种肺吸入槲皮素纳米微球及其制备方法 Download PDFInfo
- Publication number
- CN103520139A CN103520139A CN201310529762.6A CN201310529762A CN103520139A CN 103520139 A CN103520139 A CN 103520139A CN 201310529762 A CN201310529762 A CN 201310529762A CN 103520139 A CN103520139 A CN 103520139A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- quercetin
- nano microsphere
- derivatives
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 title claims abstract description 171
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 title claims abstract description 86
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 title claims abstract description 86
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229960001285 quercetin Drugs 0.000 title claims abstract description 86
- 235000005875 quercetin Nutrition 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 239000002245 particle Substances 0.000 title claims abstract description 37
- 229920001661 Chitosan Polymers 0.000 claims abstract description 117
- 210000004072 lung Anatomy 0.000 claims abstract description 55
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 31
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 24
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 18
- 239000004005 microsphere Substances 0.000 claims description 115
- 238000005507 spraying Methods 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 37
- 238000001035 drying Methods 0.000 claims description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000011259 mixed solution Substances 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 239000012982 microporous membrane Substances 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 230000002572 peristaltic effect Effects 0.000 claims description 15
- 239000007921 spray Substances 0.000 claims description 15
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 12
- -1 acyl phospholipid Chemical class 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 230000006196 deacetylation Effects 0.000 claims description 10
- 238000003381 deacetylation reaction Methods 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 238000009826 distribution Methods 0.000 description 15
- 230000002685 pulmonary effect Effects 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 238000012913 prioritisation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000004852 Lung Injury Diseases 0.000 description 5
- 206010069363 Traumatic lung injury Diseases 0.000 description 5
- 231100000515 lung injury Toxicity 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 208000019155 Radiation injury Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000011302 Brassica oleracea Nutrition 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 125000000647 trehalose group Chemical group 0.000 description 2
- IHNKQIMGVNPMTC-RUZDIDTESA-N 1-stearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C IHNKQIMGVNPMTC-RUZDIDTESA-N 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001249699 Capitata Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 150000003243 quercetin Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529762.6A CN103520139B (zh) | 2013-11-01 | 2013-11-01 | 一种肺吸入槲皮素纳米微球及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529762.6A CN103520139B (zh) | 2013-11-01 | 2013-11-01 | 一种肺吸入槲皮素纳米微球及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103520139A true CN103520139A (zh) | 2014-01-22 |
CN103520139B CN103520139B (zh) | 2015-09-23 |
Family
ID=49922730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310529762.6A Active CN103520139B (zh) | 2013-11-01 | 2013-11-01 | 一种肺吸入槲皮素纳米微球及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520139B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933028A (zh) * | 2014-04-14 | 2014-07-23 | 张维芬 | 一种用于预防和治疗急性放射性肺炎的药物 |
CN104586775A (zh) * | 2015-01-29 | 2015-05-06 | 张维芬 | 一种治疗放射性肺炎的黄芪多糖缓释微球及其制备方法 |
CN106265607A (zh) * | 2016-09-23 | 2017-01-04 | 潍坊医学院 | 一种用于肺吸入壳聚糖基纳米靶向聚合粒子及其制备方法 |
CN106309411A (zh) * | 2016-09-23 | 2017-01-11 | 潍坊医学院 | 一种槲皮素与紫杉醇共输送肺吸入纳米靶向多孔聚合粒子及其制备方法 |
RU2772020C2 (ru) * | 2017-07-17 | 2022-05-16 | Индена С.П.А. | Порошкообразные твердые дисперсии, включающие кверцетин, способ их получения и их композиции |
WO2023184828A1 (zh) * | 2022-03-30 | 2023-10-05 | 扬州日兴生物科技股份有限公司 | 一种提高壳寡糖口服生物利用度的纳米微球及其制备方法 |
-
2013
- 2013-11-01 CN CN201310529762.6A patent/CN103520139B/zh active Active
Non-Patent Citations (3)
Title |
---|
张维芬等: "氨茶碱/羧甲基壳聚糖/β-环糊精肺吸入微球的制备及特性研究", 《2010年中国药学大会暨第十届中国药师周论文集》, 31 December 2010 (2010-12-31) * |
李晶等: "壳聚糖纳米微球作为化疗药物载体的研究进展", 《广东医学》, vol. 32, no. 6, 31 March 2011 (2011-03-31) * |
胡英等: "槲皮素包合物微球的制备及其体外释放研究", 《中国药房》, vol. 23, no. 33, 7 September 2012 (2012-09-07) * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933028A (zh) * | 2014-04-14 | 2014-07-23 | 张维芬 | 一种用于预防和治疗急性放射性肺炎的药物 |
CN104586775A (zh) * | 2015-01-29 | 2015-05-06 | 张维芬 | 一种治疗放射性肺炎的黄芪多糖缓释微球及其制备方法 |
CN106265607A (zh) * | 2016-09-23 | 2017-01-04 | 潍坊医学院 | 一种用于肺吸入壳聚糖基纳米靶向聚合粒子及其制备方法 |
CN106309411A (zh) * | 2016-09-23 | 2017-01-11 | 潍坊医学院 | 一种槲皮素与紫杉醇共输送肺吸入纳米靶向多孔聚合粒子及其制备方法 |
CN106309411B (zh) * | 2016-09-23 | 2019-05-03 | 潍坊医学院 | 一种槲皮素与紫杉醇共输送肺吸入纳米靶向多孔聚合粒子及其制备方法 |
CN106265607B (zh) * | 2016-09-23 | 2019-06-11 | 潍坊医学院 | 一种用于肺吸入壳聚糖基纳米靶向聚合粒子及其制备方法 |
RU2772020C2 (ru) * | 2017-07-17 | 2022-05-16 | Индена С.П.А. | Порошкообразные твердые дисперсии, включающие кверцетин, способ их получения и их композиции |
WO2023184828A1 (zh) * | 2022-03-30 | 2023-10-05 | 扬州日兴生物科技股份有限公司 | 一种提高壳寡糖口服生物利用度的纳米微球及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103520139B (zh) | 2015-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pramanik et al. | Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases | |
CN103536583B (zh) | 一种原花青素缓释纳米微球及制备方法和应用 | |
CN103520139B (zh) | 一种肺吸入槲皮素纳米微球及其制备方法 | |
Ni et al. | Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: in vitro and in vivo characterization | |
Rubin et al. | Emerging aerosol drug delivery strategies: from bench to clinic | |
Zhou et al. | A homogenous nanoporous pulmonary drug delivery system based on metal-organic frameworks with fine aerosolization performance and good compatibility | |
CN102078312A (zh) | 一种姜黄素类化合物干粉吸入剂及其制备方法和用途 | |
Taki et al. | Fabrication of nanocomposite particles using a two-solution mixing-type spray nozzle for use in an inhaled curcumin formulation | |
JP2013536845A5 (zh) | ||
CN103768046A (zh) | 一种注射用紫杉醇纳米晶体及其制备方法 | |
CN102058566A (zh) | 一种冬凌草甲素类成分干粉吸入剂及其制备方法和用途 | |
CN101780042A (zh) | 一种紫杉醇纳米靶向缓释长循环脂质体及其制备方法 | |
CN103479583B (zh) | 一种炎琥宁肠溶干混悬剂及其制备方法 | |
Kanojia et al. | Recent advancements and applications of inhalable microparticles based drug delivery systems in respiratory disorders | |
CN106265607B (zh) | 一种用于肺吸入壳聚糖基纳米靶向聚合粒子及其制备方法 | |
CN107913261A (zh) | 一种西维来司钠干粉吸入剂及其制备方法 | |
Huang et al. | Cyclosporine A-loaded chitosan extra-fine particles for deep pulmonary drug delivery: In vitro and in vivo evaluation | |
KR101516057B1 (ko) | 폐질환 치료용 흡입 제형 및 이의 제조방법 | |
CN100348194C (zh) | 盐酸洛拉曲克的脂质体制剂及其制备方法 | |
Rawat et al. | Nanotechnology-Based Drug Delivery Systems for the Treatment of Pulmonary Diseases | |
CN1943585B (zh) | 灯盏花素前脂质体粉末制剂 | |
CN102091062A (zh) | 一种采取吸入给药紫杉醇治疗肺癌的方法 | |
CN114748429A (zh) | 一种水溶性大麻素制剂及其制备方法 | |
Mardani et al. | Preparation and characterization of Celecoxib agglomerated nanocrystals and dry powder inhalation formulations to improve its aerosolization performance | |
IL163736A (en) | Tiotropium containing powdered preparations, method of their preparation and uses thereof for the manufacture of a medicament suitable for inhalation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WEIFANG MEDICAL COLLEGE Free format text: FORMER OWNER: ZHANG WEIFEN Effective date: 20150817 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150817 Address after: 261020 Shandong Province, Weifang city Weicheng District Baotong Street No. 7166 pharmaceutical and bio Sciences Applicant after: Weifang Medical University Address before: 261053 Shandong Province, Weifang city Weicheng District Baotong Street No. 7166 pharmaceutical and bio Sciences Applicant before: Zhang Weifen |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |